Targeting p21-activated kinase 1 for development of a novel anti-arrhythmic drug class.

Yu He, Alexander Grassam-Rowe, Ming Lei, James S H Bae

Journal: Philosophical transactions of the Royal Society of London. Series B, Biological sciences 2023;378(1879):20220285

PMID: 37122206

Abstract

Evidence accumulated over the past decade suggests that p21-activated kinase 1 (PAK1) is a critical cardiac-protective signalling molecule. The present article provides an updated review of recent findings regarding the role of PAK1 in maintaining normal cardiac electrophysiological function through its regulation of membrane and Ca clocks. We first overviewed the PAK1 activation mechanism. We then discussed recent updated results showing the action mechanisms of PAK1 signalling on Cav1.2/Cav1.3 (I)-mediated Ca entry, ryanodine receptor type 2-mediated sarcoplasmic reticulum (SR) Ca release, transcriptional regulation of SR Ca-ATPase 2a, Na/Ca exchangers, and Ca/calmodulin-dependent protein kinase II. Finally, we proposed a new and exciting route for developing a PAK1-based therapeutic strategy for cardiac arrhythmias. This article is part of the theme issue 'The heartbeat: its molecular basis and physiological mechanisms'.

Address: Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.